Irish drug reimbursement system faces criticism over Skyclarys access delays

The Skyclarys reimbursement campaign highlights systemic inefficiencies in the Irish drug approval process, prioritizing bureaucratic and corporate interests over patient access. It remains unclear if the government will adjust the pricing negotiation framework to expedite access for rare disease patients.